FLAMMA's R&D Building Expansion Aims to Improve Drug Development

FLAMMA's R&D Building Expansion Aims to Improve Drug Development

By Pharma Tech Outlook | Wednesday, June 10, 2020

Gian Paolo Negrisoli, CEO, Flamma

While most of the CEOs use a gold plated shovel, Flamma's CEO Gian Paolo Negrisoli, used an excavator to mark the groundbreaking of the new R&D Building at Flamma's headquarters in Chignolod'Isola, Bergamo, Italy.

ChignoloD’Isola, Bergamo, Italy: Flamma SpA ("Flamma") is a top Contract Development and Manufacturing Organization (CDMO). The company develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. Flamma proudly announced the groundbreaking for its new R&D building on May 21, 2020. This essential milestone is an example of the commitment made to not only customers but also employees to deliver a first-class organization people want to place their projects.

This expansion at Flamma's headquarters that will quadruple its R&D space. The R&D building will allow Flamma to add 50 additional employees to the R&D workforce. The space will house chemistry and analytical development labs along with offices and meeting rooms. Special features will include a lab for high containment and unique chemistries.

The new R&D building will complement the R&D work at Flamma Malvern, USA, and PA outside of Philadelphia. Also, the team from the USA continuous to enhance as more and more projects comes on board.

FLAMMA is a firm specializing in the cGMP manufacture of APIs, NCEs, RSMs, and the advanced intermediates for the pharmaceutical industry. Being a fully integrated company, Flamma permits to move the compounds quickly along their journey, taking all the aspects necessary for the success of the project.

FLAMMA was featured in PharmaTech Outlook magazine as one of the Top 10 CMOs In Europe-2020.

Weekly Brief

Read Also